Which Dates Could Move Hims & Hers Stock Most?

Hims & Hers Health (HIMS) stock fell 30.0% in November 2026, underperforming the S&P 500. The company cut its 2026 adjusted EBITDA guidance to $267M, citing challenges in the U.K. and Germany. It faces a securities class action related to an FTC complaint. Key events include slower U.S. weight loss marketing and a push into international markets, with fiscal Q4 subscriber numbers being a focus.

Original reporting
Published Nov 12, 2026, 3:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 3:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Which Dates Could Move Hims & Hers Stock Most? — source image
Decision brief

The 30-second read

$HIMSBearishHigh
01

Why it matters

The EBITDA guidance cut reflects slower subscriber growth and higher marketing spend abroad, while the class action introduces legal risk, both likely to depress the share price in the near term.

02

Market read

New guidance and litigation news provide fresh, material information for traders to reassess HIMS positioning.

03

What to watch

Potential upside from upcoming weight‑loss product launches and possible cost efficiencies not yet disclosed.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Hims & Hers Health provides telehealth services for sexual health, hair loss, and weight loss, recently expanding internationally.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Hims & Hers cut its 2026 adjusted EBITDA guidance to $267M from $300M and disclosed a securities class action, both first reported here.

Expected impact

likely downward pressure as investors price in weaker earnings outlook and litigation risk

Evidence & confidence

The new EBITDA guidance is materially lower and the class action adds uncertainty, prompting sell‑side sentiment.

Market effects

Weight‑loss and telehealth sector may see broader scrutiny as Hims & Hers signals slower growth.

U.K. and Germany subscriber growth expectations are now more uncertain, affecting European health‑tech peers.

The guidance cut adds to overall health‑tech volatility, but impact is limited to niche segment.

Counterpoint

If the U.K. and Germany pricing strategy succeeds, the stock could rebound despite short‑term pressure.

Key entities

  • Hims & Hers Health

    U.S. telehealth provider (ticker HIMS) reporting guidance cut and class action.

  • Hagens Berman

    Law firm issuing the class‑action notice.

Related articles

$HIMSHighAI 8/10

Hims & Hers Revenue Climbs 49% as Gross Margin Falls to 57%

Hims & Hers reported Q3 2026 revenue of $890.4M, up 49% YoY, but gross margin fell to 57% from 74%. Net loss was $33M vs. $15.8M net income a year ago. Adjusted EBITDA rose to $82.4M. The company forecasts Q4 revenue of $875M-$895M and full-year revenue of $3.13B-$3.15B, but lowered adjusted EBITDA guidance to $257M-$277M.

$LLYHigh

More Good News for Eli Lilly Sends the Stock Even Higher

Eli Lilly (NYSE:LLY) shares rose after positive phase 3 trial results for retatrutide in treating knee osteoarthritis pain and weight loss. The company also partnered with Hims & Hers to expand access to GLP-1 drugs. Additionally, Lilly reported that Foundayo reduced sleep apnea severity, with FDA submission planned. Q3 revenue grew 39% to $24.4B, and earnings per share increased 16% to $7.22. Jefferies raised its price target to $1,700.

$HIMSHigh

Five States Join FTC Suit Against Hims & Hers Over Privacy Practices

Five US states joined the FTC's lawsuit against Hims & Hers, alleging deceptive privacy practices, including sharing sensitive health data with Meta and Snap. The amended complaint also accuses the company of misleading billing and cancellation practices. Hims & Hers plans to defend itself, while the FTC claims the company charges users before provider consultations and complicates cancellations. The company recently cut its full-year profit forecast due to higher costs.